Alok Dalal
Stock Analyst at Jefferies
(3.51)
# 2,260
Out of 5,070 analysts
92
Total ratings
59.7%
Success rate
6.8%
Average return
Main Sectors:
Stocks Rated by Alok Dalal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: ALKEM Alkem Laboratories Limited | Reiterated: Buy | ₹6,500 → ₹6,400 | ₹5,024 | +27.39% | 6 | Aug 20, 2026 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Reiterated: Buy | ₹9,700 → ₹10,350 | ₹7,748 | +33.58% | 5 | Aug 17, 2026 | |
| NSE: EMCURE Emcure Pharmaceuticals Limited | Reiterated: Buy | ₹2,100 → ₹2,320 | ₹1,774 | +30.76% | 9 | Aug 11, 2026 | |
| NSE: ENTERO Entero Healthcare Solutions Limited | Reiterated: Buy | ₹1,500 → ₹1,800 | ₹1,510 | +19.24% | 7 | Aug 11, 2026 | |
| NSE: GLAND Gland Pharma Limited | Upgraded: Buy | ₹2,080 → ₹3,350 | ₹2,978 | +12.50% | 5 | Aug 11, 2026 | |
| NSE: SAILIFE Sai Life Sciences Limited | Reiterated: Buy | ₹1,270 → ₹1,610 | ₹1,394 | +15.54% | 5 | Aug 11, 2026 | |
| NSE: COHANCE Cohance Lifesciences Limited | Reiterated: Sell | ₹300.00 → ₹350.00 | ₹461.25 | -24.12% | 2 | Aug 6, 2026 | |
| NSE: MEDANTA Global Health Limited | Reiterated: Buy | ₹1,500 → ₹1,660 | ₹1,239 | +34.01% | 6 | Aug 4, 2026 | |
| NSE: MANKIND Mankind Pharma Limited | Reiterated: Buy | ₹3,000 → ₹3,220 | ₹2,273 | +41.64% | 7 | Jul 31, 2026 | |
| NSE: CIPLA Cipla Limited | Reiterated: Sell | ₹1,170 | ₹1,334 | -12.26% | 8 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ₹1,100 → ₹1,700 | ₹2,070 | -17.87% | 4 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹1,380 → ₹1,500 | ₹836.70 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | ₹2,400 → ₹2,250 | ₹1,956 | n/a | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | ₹1,210 → ₹1,100 | ₹1,249 | n/a | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ₹1,620 → ₹1,700 | ₹1,273 | n/a | 3 | May 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹1,350 → ₹1,150 | ₹1,123 | n/a | 3 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ₹6,280 → ₹6,200 | ₹9,212 | n/a | 2 | May 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹260.00 | ₹198.90 | n/a | 1 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹2,850 → ₹3,140 | ₹3,309 | n/a | 2 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ₹890.00 → ₹650.00 | ₹392.55 | n/a | 2 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹860.00 → ₹850.00 | ₹738.60 | n/a | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹2,260 → ₹2,265 | ₹1,753 | n/a | 2 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | ₹400.00 | ₹342.85 | n/a | 1 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $68 → $12 | $13.26 | n/a | 4 | Jan 30, 2024 |
Alkem Laboratories Limited
Aug 20, 2026
Reiterated: Buy
Price Target: ₹6,500 → ₹6,400
Current: ₹5,024
Upside: +27.39%
Apollo Hospitals Enterprise Limited
Aug 17, 2026
Reiterated: Buy
Price Target: ₹9,700 → ₹10,350
Current: ₹7,748
Upside: +33.58%
Emcure Pharmaceuticals Limited
Aug 11, 2026
Reiterated: Buy
Price Target: ₹2,100 → ₹2,320
Current: ₹1,774
Upside: +30.76%
Entero Healthcare Solutions Limited
Aug 11, 2026
Reiterated: Buy
Price Target: ₹1,500 → ₹1,800
Current: ₹1,510
Upside: +19.24%
Gland Pharma Limited
Aug 11, 2026
Upgraded: Buy
Price Target: ₹2,080 → ₹3,350
Current: ₹2,978
Upside: +12.50%
Sai Life Sciences Limited
Aug 11, 2026
Reiterated: Buy
Price Target: ₹1,270 → ₹1,610
Current: ₹1,394
Upside: +15.54%
Cohance Lifesciences Limited
Aug 6, 2026
Reiterated: Sell
Price Target: ₹300.00 → ₹350.00
Current: ₹461.25
Upside: -24.12%
Global Health Limited
Aug 4, 2026
Reiterated: Buy
Price Target: ₹1,500 → ₹1,660
Current: ₹1,239
Upside: +34.01%
Mankind Pharma Limited
Jul 31, 2026
Reiterated: Buy
Price Target: ₹3,000 → ₹3,220
Current: ₹2,273
Upside: +41.64%
Cipla Limited
Jul 28, 2026
Reiterated: Sell
Price Target: ₹1,170
Current: ₹1,334
Upside: -12.26%
Jul 28, 2026
Reiterated: Hold
Price Target: ₹1,100 → ₹1,700
Current: ₹2,070
Upside: -17.87%
Aug 14, 2025
Reiterated: Buy
Price Target: ₹1,380 → ₹1,500
Current: ₹836.70
Upside: n/a
Aug 7, 2025
Upgraded: Buy
Price Target: ₹2,400 → ₹2,250
Current: ₹1,956
Upside: n/a
Jul 24, 2025
Reiterated: Sell
Price Target: ₹1,210 → ₹1,100
Current: ₹1,249
Upside: n/a
May 31, 2025
Reiterated: Hold
Price Target: ₹1,620 → ₹1,700
Current: ₹1,273
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: ₹1,350 → ₹1,150
Current: ₹1,123
Upside: n/a
May 18, 2025
Reiterated: Hold
Price Target: ₹6,280 → ₹6,200
Current: ₹9,212
Upside: n/a
May 15, 2025
Reiterated: Buy
Price Target: ₹260.00
Current: ₹198.90
Upside: n/a
Apr 30, 2025
Reiterated: Buy
Price Target: ₹2,850 → ₹3,140
Current: ₹3,309
Upside: n/a
Apr 25, 2025
Reiterated: Hold
Price Target: ₹890.00 → ₹650.00
Current: ₹392.55
Upside: n/a
Feb 10, 2025
Reiterated: Buy
Price Target: ₹860.00 → ₹850.00
Current: ₹738.60
Upside: n/a
Jan 31, 2025
Reiterated: Buy
Price Target: ₹2,260 → ₹2,265
Current: ₹1,753
Upside: n/a
Jan 6, 2025
Upgraded: Hold
Price Target: ₹400.00
Current: ₹342.85
Upside: n/a
Jan 30, 2024
Downgraded: Sell
Price Target: $68 → $12
Current: $13.26
Upside: n/a